CN100591762C - 抗原呈递细胞、其制备方法及其用于癌症疫苗的用途 - Google Patents

抗原呈递细胞、其制备方法及其用于癌症疫苗的用途 Download PDF

Info

Publication number
CN100591762C
CN100591762C CN02815007A CN02815007A CN100591762C CN 100591762 C CN100591762 C CN 100591762C CN 02815007 A CN02815007 A CN 02815007A CN 02815007 A CN02815007 A CN 02815007A CN 100591762 C CN100591762 C CN 100591762C
Authority
CN
China
Prior art keywords
cells
adhapi
pbmc
pwm
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN02815007A
Other languages
English (en)
Chinese (zh)
Other versions
CN1537161A (zh
Inventor
R·德桑提斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aipigen Treatment LLC
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN1537161A publication Critical patent/CN1537161A/zh
Application granted granted Critical
Publication of CN100591762C publication Critical patent/CN100591762C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN02815007A 2001-07-30 2002-07-25 抗原呈递细胞、其制备方法及其用于癌症疫苗的用途 Expired - Lifetime CN100591762C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2001/000419 WO2003012085A1 (en) 2001-07-30 2001-07-30 Antigen presenting cells, method for their preparation and their use for cancer vaccines
ITPCT/IT01/00419 2001-07-30

Publications (2)

Publication Number Publication Date
CN1537161A CN1537161A (zh) 2004-10-13
CN100591762C true CN100591762C (zh) 2010-02-24

Family

ID=11133712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN02815007A Expired - Lifetime CN100591762C (zh) 2001-07-30 2002-07-25 抗原呈递细胞、其制备方法及其用于癌症疫苗的用途

Country Status (16)

Country Link
US (3) US20030119187A1 (enExample)
EP (1) EP1412485B1 (enExample)
JP (1) JP2004536615A (enExample)
KR (1) KR100916670B1 (enExample)
CN (1) CN100591762C (enExample)
AT (1) ATE505533T1 (enExample)
AU (1) AU2002334387B2 (enExample)
BR (1) BR0211520A (enExample)
CA (1) CA2453522C (enExample)
DE (1) DE60239741D1 (enExample)
DK (1) DK1412485T3 (enExample)
ES (1) ES2367256T3 (enExample)
HU (1) HUP0401753A3 (enExample)
MX (1) MXPA04000885A (enExample)
PL (1) PL211907B1 (enExample)
WO (2) WO2003012085A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
KR101192652B1 (ko) * 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7833775B2 (en) * 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
KR20060129393A (ko) * 2004-01-20 2006-12-15 아이치 프레펙츄러 ＨＬＡ－Ａ2402-제한 Ｅｐ－ＣＡＭ 특이적 ＣＴＬ에인식되는 에피토프/펩티드 및 그 용도
JP4925033B2 (ja) * 2004-02-03 2012-04-25 学校法人 久留米大学 ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
EP2698430A3 (en) * 2009-12-08 2014-03-05 Wilson Wolf Manufacturing Corporation Methods of cell culture for adoptive cell therapy
US20130011488A1 (en) * 2011-07-07 2013-01-10 Nezami Md Mohammad Systems, Methods, and Formulations for Treating Cancer
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
PL2914254T3 (pl) * 2012-10-30 2020-09-07 Mei Pharma, Inc. Terapie skojarzone w leczeniu nowotworów chemoodpornych
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
JP2018515421A (ja) * 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造
MX2018000016A (es) 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Composiciones farmaceuticas liofilizadas.
CN105132371B (zh) * 2015-07-24 2016-05-25 北京鼎成肽源生物技术有限公司 体外提呈、激活dc细胞的方法及其应用
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CA3071755A1 (en) 2017-08-03 2019-02-07 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
CN107557333B (zh) * 2017-10-16 2018-07-31 北京鼎成肽源生物技术有限公司 一种用于细胞治疗的新抗原呈递细胞的制备方法
US12213958B2 (en) 2017-11-17 2025-02-04 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR102319259B1 (ko) 2019-07-26 2021-10-28 정재웅 지반천공기용 확장리더 안전제어장치
WO2021027057A1 (zh) * 2019-08-15 2021-02-18 成都冕康生物科技有限公司 一种针对ebv病毒抗原的b细胞疫苗及其制备方法
CN114099655A (zh) * 2021-11-16 2022-03-01 苏州大学 一种预防或治疗癌症的疫苗系统及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
CN1278739A (zh) * 1997-09-15 2001-01-03 遗传免疫有限公司 向皮肤抗原呈递细胞传递基因的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
CN1278739A (zh) * 1997-09-15 2001-01-03 遗传免疫有限公司 向皮肤抗原呈递细胞传递基因的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Heterogeneous expression of the SSX cancer/testis antigensin human melanoma lesions and cell lines. DOS SANTOS NUNO R等.CANCER RESEARCH,Vol.60. 2000 *
Heterogeneous expression of the SSX cancer/testis antigensin human melanoma lesions and cell lines.. DOS SANTOS NUNO R等.CANCER RESEARCH,Vol.60 . 2000

Also Published As

Publication number Publication date
MXPA04000885A (es) 2004-06-03
US20050002920A1 (en) 2005-01-06
US7883889B2 (en) 2011-02-08
US20040185563A1 (en) 2004-09-23
ES2367256T3 (es) 2011-10-31
KR100916670B1 (ko) 2009-09-08
KR20040021662A (ko) 2004-03-10
DE60239741D1 (de) 2011-05-26
EP1412485B1 (en) 2011-04-13
DK1412485T3 (da) 2011-08-01
WO2003012086A1 (en) 2003-02-13
EP1412485A1 (en) 2004-04-28
HUP0401753A2 (hu) 2004-11-29
US20030119187A1 (en) 2003-06-26
AU2002334387B2 (en) 2007-10-04
JP2004536615A (ja) 2004-12-09
PL367617A1 (en) 2005-03-07
BR0211520A (pt) 2004-09-14
CN1537161A (zh) 2004-10-13
CA2453522A1 (en) 2003-02-13
ATE505533T1 (de) 2011-04-15
HK1068913A1 (zh) 2005-05-06
PL211907B1 (pl) 2012-07-31
HUP0401753A3 (en) 2011-04-28
CA2453522C (en) 2013-04-30
WO2003012085A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
CN100591762C (zh) 抗原呈递细胞、其制备方法及其用于癌症疫苗的用途
AU2002334387A1 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
JP5452231B2 (ja) 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン
JP4662776B2 (ja) 抗原負荷した樹状細胞ワクチンを前駆体から発生させる迅速ワンステップ法
ES2335396T3 (es) Composicion farmaceutica para inducir una respuesta inmune en un ser humano o animal.
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
JP2002529073A (ja) 三次元装置における造血前駆細胞からのリンパ様組織特異的細胞の生成
Kalady et al. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells
WO2002053176A2 (en) An autologous anti-cancer vaccine
ES2340358T3 (es) Uso de lineas celulares alogenicas para cargar celulas que presentan antigenos para elicitar respuestas inmunes.
Osman et al. Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts.
Piemonti et al. Generation and functional characterisation of dendritic cells from patients with pancreatic carcinoma with special regard to clinical applicability
Wang et al. Effect of dendritic cell vaccine against a tongue squamous cell cancer cell line (Tca8113) in vivo and in vitro
Vichchatorn et al. Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme
HK1068913B (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
RU2267326C2 (ru) Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями
WO2001062092A1 (en) Formulations and methods for using the same to elicit an immune response
WO1998048000A2 (en) A cell strain with activated anti-cancer cytotoxic activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068913

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1068913

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: EPIGEN TREATMENT LTD.

Free format text: FORMER OWNER: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

Effective date: 20120611

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120611

Address after: Italy Pordenone

Patentee after: Aipigen treatment LLC

Address before: Rome Italy

Patentee before: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

CX01 Expiry of patent term

Granted publication date: 20100224

CX01 Expiry of patent term